Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Pharmalicensing Logo - Go to Home page
Save this technology
close
Save to Existing Project
Save to a New Project
CD151: A Novel Anti-Inflammatory Regulator
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1485
The surveillance of the body for foreign antigens is a critical function of the immune system. Accordingly, B and T lymphocytes continually patrol the body for foreign...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

The surveillance of the body for foreign antigens is a critical function of the immune system. Accordingly, B and T lymphocytes continually patrol the body for foreign antigens by circulating from the blood, through tissues, into lymph nodes, and back to the blood. The continuous recirculation of lymphocytes and their movement from the blood into peripheral tissues is a central feature of immune surveillance, but also contributes to the pathogenesis of inflammatory diseases, autoimmune diseases, and the development and progression of allergic responses.

Aims/Hypothesis

We are investigating the down-regulation of CD151 as a means for treating inflammation.

Results

In the present invention it has been uncovered that CD151 expression in T cells plays a key role in T cell migration and homing to the lymph nodes. The impaired homing of T lymphocytes to the peripheral lymph nodes results in attenuated progression of both asthma and adjuvant arthritis. Thus, a blocking agent for the activity or expression of CD151 can exert global suppressive effects on T-cell trafficking and differentiation within peripheral lymph nodes, and may be clinically beneficial as an anti-inflammatory agent.

Conclusion

The current invention targets the activity or expression of CD151, a molecule role involved in T cell migration, for treating inflammation.

Relevance/Opportunity

Treatment of inflammation and other conditions which involve an inflammatory response (eg,. autoimmune diseases, allergic diseases, graft rejection diseases). Please enquire quoting reference no. 1485 regarding licensing or codevelopment partnerships.
FEATURED
Last Updated May 2015
Technology Type MECHANISM
Phase of Development PRECLINICAL
CORPORATION